Increasing demand for one-time therapies for metabolic disorders and rising prevalence of lifestyle diseases are the key factors that are expected to boost the growth of this market.
According to this study, over the next five years the Metabolic Disorder Therapeutics market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global revenue market share of key companies in Metabolic Disorder Therapeutics business, shared in Chapter 3.
This report presents a comprehensive overview, market shares and growth opportunities of Metabolic Disorder Therapeutics market by product type, application, key companies and key regions.
This study considers the Metabolic Disorder Therapeutics value generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019 in Section 2.3; and forecast to 2024 in section 10.7.
Lysosomal Storage Diseases
Diabetes
Inherited Metabolic Disorders
Hypercholesterolemia
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 10.8.
Oral
Parenteral
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Novo Nordisk A/S
Sanofi S.A.
Boehringer Ingelheim GmbH
Eli Lilly and Company
Merck KgaA
Amgen, Inc.
AstraZeneca PLC
Actelion Pharmaceuticals Ltd.
Shire PLC
AbbVie, Inc.
Biocon Ltd.
BioMarin Pharmaceutical, Inc.
Bristol-Myers Squibb Company
Cipla, Inc.
CymaBay Therapeutics, Inc.
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Metabolic Disorder Therapeutics market size by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Metabolic Disorder Therapeutics market by identifying its various subsegments.
Focuses on the key global Metabolic Disorder Therapeutics players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Metabolic Disorder Therapeutics with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the size of Metabolic Disorder Therapeutics submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
